Apellis Pharmaceuticals Total Assets 2011-2026 | APLS

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Apellis Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.08 B	885 M	789 M	760 M	882 M	961 M	389 M	204 M	182 M	27.4 M	38.2 M	14.3 M	5.2 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.08 B	5.2 M	478 M

Quarterly Total Assets Apellis Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
821 M	807 M	885 M	902 M	904 M	832 M	789 M	818 M	916 M	979 M	760 M	873 M	1 B	1.15 B	882 M	526 M	700 M	810 M	961 M	961 M	961 M	961 M	389 M	389 M	389 M	389 M	204 M	204 M	204 M	204 M	182 M	182 M	182 M	182 M	27.4 M	27.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.15 B	27.4 M	621 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	1.36 B	$ 3.58	0.42 %	$ 1.07 B	Canada
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
AC Immune SA ACIU	231 M	$ 3.22	2.88 %	$ 229 M	Schweiz
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	16.1 M	$ 0.79	-	$ 4.31 M	China
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	62.2 M	-	10.36 %	$ 9.8 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	529 M	$ 4.2	-0.47 %	$ 105 M	Schweiz
argenx SE ARGX	6.2 B	$ 708.98	0.81 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	1.3 B	$ 231.11	0.03 %	$ 5 B	Danmark
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.45	-4.43 %	$ 8.3 B	Australia
Atea Pharmaceuticals AVIR	315 M	$ 6.02	-0.5 %	$ 491 M	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Arcturus Therapeutics Holdings ARCT	271 M	$ 6.59	-0.6 %	$ 180 M	Israel
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
BioCardia BCDA	2.99 M	$ 1.29	1.57 %	$ 27.3 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Anika Therapeutics ANIK	271 M	$ 14.36	-	$ 210 M	USA
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Aptose Biosciences APTO	10.1 M	-	-45.71 %	$ 1.2 M	Canada
AVEO Pharmaceuticals AVEO	105 M	-	-	$ 521 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
BioNTech SE BNTX	22 B	$ 91.71	1.29 %	$ 27.2 B	Germany
Aytu BioScience AYTU	124 M	$ 2.64	-	$ 16.6 M	USA
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Burford Capital Limited BUR	3.11 B	$ 8.17	1.49 %	$ 1.33 B	Britain
Autolus Therapeutics plc AUTL	783 M	$ 1.51	-0.33 %	$ 385 M	Britain
Athira Pharma ATHA	58.8 M	-	-	$ 269 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
Can-Fite BioPharma Ltd. CANF	9.12 M	$ 3.58	-0.28 %	$ 7.79 B	Israel